…
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 4514.00M | 3492.00M | 3673.00M | 2683.00M | 2281.00M |
| Net income | 3246.00M | 2993.00M | 3165.00M | 2358.00M | 1994.00M |
| Selling general administrative | 8221.00M | 7685.00M | 7129.00M | 6035.00M | 5752.00M |
| Gross profit | 16065.00M | 13980.00M | 12494.00M | 11578.00M | 10968.00M |
| Reconciled depreciation | 1193.00M | 1050.00M | 1028.00M | 998.00M | 990.00M |
| Ebit | 5121.00M | 3888.00M | 4029.00M | 2841.00M | 2584.00M |
| Ebitda | 6314.00M | 4938.00M | 5057.00M | 4241.00M | 3780.00M |
| Depreciation and amortization | 1193.00M | 1050.00M | 1028.00M | 1400.00M | 1196.00M |
| Non operating income net other | - | - | - | -158.00M | -303.00M |
| Operating income | 4889.00M | 5061.00M | 4281.00M | 2841.00M | 2584.00M |
| Other operating expenses | 20227.00M | 17534.00M | 16217.00M | 15407.00M | 14421.00M |
| Interest expense | 607.00M | 396.00M | 356.00M | 158.00M | 509.00M |
| Tax provision | 1268.00M | 499.00M | 508.00M | 325.00M | 287.00M |
| Interest income | 486.00M | 257.00M | 281.00M | 243.00M | 269.00M |
| Net interest income | -607.00M | -409.00M | -363.00M | - | - |
| Non recurring | - | - | - | 216.00M | - |
| Income tax expense | 1268.00M | 499.00M | 508.00M | 325.00M | 287.00M |
| Total revenue | 25116.00M | 22595.00M | 20498.00M | 18449.00M | 17108.00M |
| Total operating expenses | 11176.00M | 8919.00M | 8213.00M | 8536.00M | 8281.00M |
| Cost of revenue | 9051.00M | 8615.00M | 8004.00M | 6871.00M | 6140.00M |
| Total other income expense net | -375.00M | -1569.00M | -608.00M | -158.00M | -303.00M |
| Net income from continuing ops | 3246.00M | 2993.00M | 3165.00M | 2358.00M | 1994.00M |
| Net income applicable to common shares | 3246.00M | 2993.00M | 3165.00M | 2358.00M | 1994.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 47844.00M | 42971.00M | 39912.00M | 36884.00M | 34631.00M |
| Intangible assets | 5681.00M | 4395.00M | 4593.00M | 4885.00M | 4840.00M |
| Other current assets | 1306.00M | 1684.00M | 857.00M | 787.00M | 662.00M |
| Total liab | 25424.00M | 22337.00M | 21319.00M | 20268.00M | 19754.00M |
| Total stockholder equity | 22420.00M | 20634.00M | 18593.00M | 16616.00M | 14877.00M |
| Other current liab | 4842.00M | 3989.00M | 3776.00M | 3699.00M | 3413.00M |
| Common stock | 38.00M | 38.00M | 38.00M | 38.00M | 38.00M |
| Capital stock | 38.00M | 38.00M | 38.00M | 38.00M | 38.00M |
| Retained earnings | 20472.00M | 18528.00M | 16771.00M | 14765.00M | 13480.00M |
| Other liab | - | - | - | 1751.00M | 2733.00M |
| Good will | 19291.00M | 15855.00M | 15243.00M | 14880.00M | 12918.00M |
| Other assets | 4241.00M | 3910.00M | 3849.00M | 3874.00M | 4023.00M |
| Cash | 4011.00M | 3652.00M | 2971.00M | 1844.00M | 2944.00M |
| Cash and equivalents | 4011.00M | 3652.00M | 2971.00M | 1844.00M | 2944.00M |
| Total current liabilities | 7794.00M | 7616.00M | 7921.00M | 6303.00M | 4549.00M |
| Current deferred revenue | - | - | 1551.00M | - | - |
| Net debt | 12349.00M | 9945.00M | 10523.00M | 11204.00M | 9528.00M |
| Short term debt | 1153.00M | 1409.00M | 2237.00M | 1191.00M | 7.00M |
| Short long term debt | 1000.00M | 1409.00M | 2094.00M | 1191.00M | 7.00M |
| Short long term debt total | 16360.00M | 1409.00M | 13494.00M | 13048.00M | 12472.00M |
| Other stockholder equity | 2597.00M | 2361.00M | 2200.00M | 2034.00M | 1890.00M |
| Property plant equipment | 3876.00M | 3964.00M | 3709.00M | 2970.00M | 2833.00M |
| Total current assets | 14755.00M | 14847.00M | 12518.00M | 10275.00M | 10017.00M |
| Net tangible assets | - | - | - | -3149.00M | -2881.00M |
| Short term investments | 89.00M | 750.00M | 82.00M | 84.00M | 75.00M |
| Net receivables | 4039.00M | 3987.00M | 3765.00M | 3565.00M | 3022.00M |
| Long term debt | 14859.00M | 12188.00M | 10901.00M | 11857.00M | 12472.00M |
| Inventory | 5310.00M | 4774.00M | 4843.00M | 3995.00M | 3314.00M |
| Accounts payable | 1799.00M | 1679.00M | 1517.00M | 1413.00M | 1129.00M |
| Accumulated other comprehensive income | -687.00M | -293.00M | -416.00M | -221.00M | -531.00M |
| Common stock total equity | - | - | - | 38.00M | 38.00M |
| Retained earnings total equity | - | - | - | 14765.00M | 13480.00M |
| Non currrent assets other | 2622.00M | 2684.00M | 2177.00M | 2464.00M | 2263.00M |
| Non current assets total | 33089.00M | 28124.00M | 27394.00M | 26609.00M | 24614.00M |
| Long term debt total | 14859.00M | 12188.00M | 10901.00M | 11857.00M | 12472.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 750.00M | -3000.00M | -972.00M | -2924.00M | -859.00M |
| Change to liabilities | - | - | - | 223.00M | 325.00M |
| Total cashflows from investing activities | -4866.00M | -3000.00M | -962.00M | -2924.00M | -859.00M |
| Net borrowings | 1579.00M | 940.00M | -277.00M | 472.00M | -1153.00M |
| Total cash from financing activities | 113.00M | -525.00M | -1594.00M | -749.00M | -2365.00M |
| Change to operating activities | - | - | - | 64.00M | 279.00M |
| Net income | 3246.00M | 2993.00M | 3165.00M | 2358.00M | 1994.00M |
| Change in cash | 359.00M | 681.00M | 1127.00M | -1100.00M | 1.00M |
| Begin period cash flow | 3652.00M | 2971.00M | 1844.00M | 2944.00M | 2943.00M |
| End period cash flow | 4011.00M | 3652.00M | 2971.00M | 1844.00M | 2944.00M |
| Total cash from operating activities | 5044.00M | 4242.00M | 3711.00M | 2624.00M | 3263.00M |
| Depreciation | 1193.00M | 1050.00M | 1028.00M | 998.00M | 990.00M |
| Other cashflows from investing activities | -60.00M | 43.00M | 1.00M | -2336.00M | 5.00M |
| Dividends paid | 1284.00M | 1219.00M | 1139.00M | 1051.00M | 950.00M |
| Change to inventory | -297.00M | -206.00M | -797.00M | -762.00M | -189.00M |
| Change to account receivables | 127.00M | -321.00M | -175.00M | -579.00M | -377.00M |
| Sale purchase of stock | -149.00M | -195.00M | -155.00M | - | 0.00M |
| Other cashflows from financing activities | -33.00M | -51.00M | -23.00M | 955.00M | -264.00M |
| Change to netincome | - | - | - | 454.00M | 464.00M |
| Capital expenditures | 761.00M | 755.00M | 575.00M | 588.00M | 525.00M |
| Change receivables | - | - | - | -579.00M | -377.00M |
| Cash flows other operating | - | - | - | -68.00M | 56.00M |
| Cash and cash equivalents changes | - | - | - | -1049.00M | 39.00M |
| Change in working capital | -373.00M | -683.00M | -500.00M | -732.00M | 279.00M |
| Stock based compensation | 243.00M | 229.00M | 205.00M | 168.00M | 171.00M |
| Other non cash items | 343.00M | 1023.00M | 19.00M | -226.00M | 66.00M |
| Free cash flow | 4283.00M | 3487.00M | 3136.00M | 2036.00M | 2738.00M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SYK Stryker Corporation |
3.74 1.22% |
310.55 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| ABT Abbott Laboratories |
- -% |
109.40 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.41 0.41% |
98.88 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SEMHF Siemens Healthineers AG |
0.66 1.38% |
48.35 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
| SMMNY Siemens Healthineers AG ADR |
-0.14 0.58% |
24.12 | 39.49 | 21.10 | 3.01 | 3.25 | 2.95 | 16.92 |
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
| Name | Title | Year Born |
|---|---|---|
| Mr. Kevin A. Lobo | Chairman, CEO & Pres | 1965 |
| Mr. Glenn S. Boehnlein | VP & CFO | 1962 |
| Mr. Timothy John Scannell | Exec. Advisor | 1965 |
| Mr. Viju S. Menon | Group Pres of Global Quality & Operations | 1968 |
| Mr. J. Andrew Pierce | Group Pres of MedSurg & Neurotechnology | 1974 |
| Mr. Spencer S. Stiles | Group Pres of Orthopaedics & Spine | 1977 |
| Mr. William E. Berry Jr. | VP & Chief Accounting Officer | 1966 |
| Mr. Robert C. Cohen | CTO and VP of Global R&D - Joint Replacement | NA |
| Mr. Alan Douville | VP, Chief Information Officer & Chief Information Security Officer | NA |
| Mr. Jason Beach | VP of Investor Relations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.